A Multicenter, Adaptive, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of XC221, Tablets, 100 mg in Patients With Mild COVID-19
Latest Information Update: 31 Jul 2023
At a glance
- Drugs XC-221 (Primary)
- Indications COVID 2019 infections
- Focus Registrational; Therapeutic Use
- Sponsors RSV Therapeutics
- 25 Jul 2023 Status changed from recruiting to completed.
- 23 Aug 2022 Planned End Date changed from 1 Dec 2021 to 1 Dec 2022.
- 23 Aug 2022 Planned primary completion date changed from 1 Dec 2021 to 1 Dec 2022.